The scrutiny follows an July 29, 2026, lawsuit from the Federal Trade Commission, which alleges Hims engaged in deceptive privacy practices. According to the complaint, the company shared private medical information with third-party advertisers, including Meta Platforms and Snap. Shares tumbled 14.73% to $25.00 following the announcement.

Pressure on the company intensified in August when Bloomberg reported that Visa Inc. placed Hims in its Acquirer Monitoring Program. The move stemmed from an surge in credit card disputes related to the company’s weight-loss subscription business. Internal documents indicate the company faces an $8 surcharge per dispute, leading to a projected $75,000 bill due in September. Following this report, Hims stock dropped another 7.99% to close at $31.08 on August 24, 2026. Investors seeking to participate in the investigation are directed to contact Danielle Peyton at Pomerantz LLP.